Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001829126-25-000026
Filing Date
2025-01-03
Accepted
2025-01-03 16:05:25
Documents
48
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q titanpharma_10q.htm   iXBRL 10-Q 620196
2 EXHIBIT 31.1 titanpharma_ex31-1.htm EX-31.1 14323
3 EXHIBIT 31.2 titanpharma_ex31-2.htm EX-31.2 14227
4 EXHIBIT 32.1 titanpharma_ex32-1.htm EX-32.1 6206
5 EXHIBIT 32.2 titanpharma_ex32-2.htm EX-32.2 6234
  Complete submission text file 0001829126-25-000026.txt   3119112

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ttnp-20240930.xsd EX-101.SCH 23174
7 XBRL CALCULATION FILE ttnp-20240930_cal.xml EX-101.CAL 33636
8 XBRL DEFINITION FILE ttnp-20240930_def.xml EX-101.DEF 66395
9 XBRL LABEL FILE ttnp-20240930_lab.xml EX-101.LAB 234453
10 XBRL PRESENTATION FILE ttnp-20240930_pre.xml EX-101.PRE 180510
50 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_10q_htm.xml XML 351103
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-13341 | Film No.: 25505972
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)